Other diseases

The G-BA defines the category other as including diagnostic products used as stress triggers for myocardial perfusion imaging, for example, as well as preparations for the prevention of side effects such as chemotherapy-related nausea and those medicinal products that cannot be assigned to any other group. In this therapeutic area, 23 medicinal products have so far been evaluated in 30 procedures with a total of 35 subpopulations. A major additional benefit has been identified for a weighted 1.1% of these subpopulations, with a considerable additional benefit for 6.7%%. Proof of a minor additional benefit for 6% of the subpopulations and of a non-quantifiable additional benefit for 32.2% has been seen.

The G-BA has seen no additional benefit proven for 54% of the subpopulations. This corresponds to 74% of the total 8.72 million patients who fall within the indication areas of the assessed medicinal products and for whom the G-BA therefore sees no proof of additional benefit.